Novavax, Inc.: Buy the Dip?

Novavax's (NASDAQ: NVAX) investors can't seem to catch a break. The clinical-stage vaccine maker has been down on its luck ever since it released disappointing phase 3 trial results last year for its lead product candidate. The markets responded to the news by wiping away 85% of the company's market cap in a single day. Shares have remained on a downward slide ever since.

The stock recently woke up after management announced that it would be holding a special conference call with investors to share a series of clinical updates. However, despite the mostly positive news, traders dumped the shares as soon as the results became public. 

So, if the news was good and the share price fell, is it a good time to consider getting in?

Continue reading

Source: Fool.com